LSLeroy Storsley

Leroy Storsley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leroy Storsley has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of an exercise rehabilitation program on physical function over 1 year in chronic kidney disease: an observational study

    by Nicholas Hargrove, Quinn Tays, Leroy Storsley, Paul Komenda, Claudio Rigatto, Thomas Ferguson, Navdeep Tangri, Clara Bohm

    Exercise rehabilitation may help maintain physical function in chronic kidney disease (CKD), but long-term clinical effectiveness is unknown. We evaluated the effect of an exercise rehabilitation program on physical function over 1 year in individuals with CKD. This clinical program evaluation included adults with CKD (any stage) registered in a provincial renal program from 1 January 2011 to 31 March 2016. Attenders were referred to and attended a 10-week exercise rehabilitation program (n = 117). Nonattenders were referred, but did not attend the program (n = 133). Individuals enrolled in a longitudinal frailty study (n = 318) composed a second control group. Primary outcome: Change in physical function [short physical performance battery (SPPB) score]. Secondary outcomes included change in health-related quality of life, physical activity, exercise behaviour, hospitalization over 1 year. Predictors of improved SPPB were assessed using logistic regression. In sum, 53, 40 and 207 participants completed 1-year follow-up in attender, nonattender and second control groups, respectively. Baseline median SPPB [interquartile range (IQR)] scores were 10.5 (9–12), 10 (8–12) and 9 (7–11) in attender, nonattender and second control groups, respectively (P = 0.02). Mean change in SPPB score over 1 year was not significantly different between groups (P = 0.7). Attenders with baseline SPPB score  = 0.07]. More attenders (60%) exercised regularly at 1 year than nonattenders (35%) (P = 0.03). The impact of clinical exercise rehabilitation programs on physical function at 1 year needs further delineation. However, our observation of improved exercise behaviour at 1 year suggests sustained benefits with such programs in CKD.


  • Open Access

    Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies

    by Steven Habbous, Jennifer Arnold, Mehmet A. Begen, Neil Boudville, Matthew Cooper, Christine Dipchand, Stephanie N. Dixon, Liane S. Feldman, Dariusz Goździk, Martin Karpinski, et al.


  • Open Access

    Impact of Exercise Counseling on Physical Function in Chronic Kidney Disease: An Observational Study

    by Clara J. Bohm, Leroy J. Storsley, Brett M. Hiebert, Serena Nelko, Navdeep Tangri, Lawrence J. Cheskin, Mara A. McAdams-DeMarco, Claudio Rigatto

    Individuals with chronic kidney disease (CKD) have low levels of physical activity and physical function. Although guidelines endorse exercise counseling for individuals with CKD, it is not yet part of routine care. We investigated the effect of attending a real-life exercise counseling clinic (ECC) on physical function in individuals with CKD. Retrospective analysis of prospectively collected observational data with quasi-experimental design. Patients with all stages of CKD registered in a large provincial renal program were eligible. The exposed cohort who attended the ECC between January 1, 2011, and March 15, 2014, included 214 individuals. The control cohort included 292 individuals enrolled in an observational study investigating longitudinal change in frailty during the same time period. Attendance at an ECC. Change in physical function as measured by Short Physical Performance Battery (SPPB) score, physical activity level (Human Activity Profile [HAP]/Physical Activity Scale for the Elderly [PASE]), and health-related quality of life (HRQOL; EQ5D/VAS) over 1 year. Eighty-seven individuals in the ECC cohort and 125 participants in the control cohort completed 1-year follow-up. Baseline median SPPB score was 10 (interquartile range [IQR]: 9-12) and 9 (IQR: 7-11) in the ECC and control cohorts, respectively (P < .01). At 1 year, SPPB scores were 10 (IQR: 8-12) and 9 (IQR: 6-11) in the ECC and control cohorts, respectively (P = .04). Mean change in SPPB over 1 year was not significantly different between groups: −0.33 (95% confidence interval [CI]: −0.81 to 0.15) in ECC and −0.22 (95% CI: −0.61 to 0.17) in control (P = .72). There was no significant difference in the proportion of individuals in each cohort with an increase/decrease in SPPB score over time. There was no significant change in physical activity or HRQOL over time between groups. Quasi-experimental design, low rate of follow-up attendance. In this pragmatic study, exercise counseling had no significant effect on change in SPPB score, suggesting that a single exercise counseling session alone is inadequate to improve physical function in CKD.


  • Cognitive Impairment in Advanced Chronic Kidney Disease: The Canadian Frailty Observation and Interventions Trial

    by Rukhsana Foster, Simon Walker, Ranveer Brar, Brett Hiebert, Paul Komenda, Claudio Rigatto, Leroy Storsley, Bhanu Prasad, Clara Bohm, Navdeep Tangri

    Background: Chronic kidney disease (CKD) affects more than one third of older adults, and is a strong risk factor for vascular disease and cognitive impairment. Cognitive impairment can have detrimental effects on the quality of life through decreased treatment adherence and poor nutrition and results in increased costs of care and early mortality. Though widely studied in hemodialysis populations, little is known about cognitive impairment in patients with pre-dialysis CKD. Methods: Multicenter, cross-sectional, prospective cohort study including 385 patients with CKD stages G4-G5. Cognitive function was measured with a validated tool called the Montreal Cognitive Assessment (MoCA) as part of a comprehensive frailty assessment in the Canadian Frailty Observation and Interventions Trial. Cognitive impairment was defined as a MoCA score of ≤24. We determined the prevalence and risk factors for cognitive impairment in patients with CKD stages G4-G5, not on dialysis. Results: Two hundred and thirty seven participants (61%) with CKD stages G4-G5 had cognitive impairment at baseline assessment. When compared to a control group, this population scored lower in all domains of cognition, with the most pronounced deficits observed in recall, attention, and visual/executive function (p < 0.01 for all comparisons). Older age, recent history of falls and history of stroke were independently associated with cognitive impairment. Conclusions: Our study uncovered a high rate of unrecognized cognitive impairment in an advanced CKD population. This impairment is global, affecting all aspects of cognition and is likely vascular in nature. The longitudinal trajectory of cognitive function and its effect on dialysis decision-making and outcomes deserves further study.


  • P044 C1q status and titer of de novo donor specific antibodies are not predictors of allograft survival

    by Chris Wiebe, Alison Gareau, Denise Pochinco, Ian Gibson, Julie Ho, Patricia Birk, Tom Blydt-Hansen, Martin Karpinski, Aviva Goldberg, Leroy Storsley, et al.

  • Open Access

    Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10

    by Julie Ho, Atul Sharma, Rupasri Mandal, David S. Wishart, Chris Wiebe, Leroy Storsley, Martin Karpinski, Ian W. Gibson, Peter W. Nickerson, David N. Rush

    Background: The goal of this study was to characterize urinary metabolomics for the noninvasive detection of cellular inflammation and to determine if adding urinary chemokine ligand 10 (CXCL10) improves the overall diagnostic discrimination. Methods: Urines (n = 137) were obtained before biopsy in 113 patients with no (n = 66), mild (borderline or subclinical; n = 58), or severe (clinical; n = 13) rejection from a prospective cohort of adult renal transplant patients (n = 113). Targeted, quantitative metabolomics was performed with direct flow injection tandem mass spectrometry using multiple reaction monitoring (ABI 4000 Q-Trap). Urine CXCL10 was measured by enzyme-linked immunosorbent assay. A projection on latent structures discriminant analysis was performed and validated using leave-one-out cross-validation, and an optimal 2-component model developed. Chemokine ligand 10 area under the curve (AUC) was determined and net reclassification index and integrated discrimination index analyses were performed. Results: PLS2 demonstrated that urinary metabolites moderately discriminated the 3 groups (Cohen κ, 0.601; 95% confidence interval [95% CI], 0.46-0.74; P < 0.001). Using binary classifiers, urinary metabolites and CXCL10 demonstrated an AUC of 0.81 (95% CI, 0.74-0.88) and 0.76 (95% CI, 0.68-0.84), respectively, and a combined AUC of 0.84 (95% CI, 0.78-0.91) for detecting alloimmune inflammation that was improved by net reclassification index and integrated discrimination index analyses. Urinary CXCL10 was the best univariate discriminator, followed by acylcarnitines and hexose. Conclusions: Urinary metabolomics can noninvasively discriminate noninflamed renal allografts from those with subclinical and clinical inflammation, and the addition of urine CXCL10 had a modest but significant effect on overall diagnostic performance. These data suggest that urinary metabolomics and CXCL10 may be useful for noninvasive monitoring of alloimmune inflammation in renal transplant patients.


  • The assessment of frailty in older people with chronic kidney disease

    by Clara Bohm, Leroy Storsley, Navdeep Tangri

    Frailty is common in chronic kidney disease (CKD) and is a predictor of adverse outcomes. The current article reviews the most common frailty measures available, gives an overview of their use in the chronic kidney disease population, and summarizes their strengths and limitations. Frailty is increasingly recognized as a potent predictor of adverse outcomes in all stages of chronic kidney disease. Recent investigations have demonstrated that the clinical perception of frailty by healthcare personnel or patients themselves is an inaccurate measure of frailty. The clinical frailty scale, a simple point-of-care tool for the assessment of frailty, has been shown to be a predictor of mortality in individuals on dialysis. The Fried criteria have been most extensively used in chronic kidney disease. However, other criteria using self-reported outcomes, clinical and cognitive criteria have also been shown to predict adverse outcomes and may be more applicable in clinical settings. Many of these still require further validation in the chronic kidney disease population.


  • Open Access

    Kidney Paired Donation Protocol for Participating Donors 2014

    by Robert Richardson, Maureen Connelly, Christine Dipchand, Amit X. Garg, Anand Ghanekar, Isabelle Houde, Olwyn Johnston, Rahul Mainra, Ruth McCarrell, Thomas Mueller, et al.


  • Top Cited Papers
    Open Access

    Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific Antibody

    by C. Wiebe, I. W. Gibson, T. D. Blydt‐Hansen, D. Pochinco, P. E. Birk, J. Ho, M. Karpinski, A. Goldberg, L. Storsley, D. N. Rush, et al.


  • Top Cited Papers

    Gestational Hypertension and Preeclampsia in Living Kidney Donors

    by Amit X. Garg, Immaculate F. Nevis, Eric McArthur, Jessica M. Sontrop, John J. Koval, Ngan N. Lam, Ainslie M. Hildebrand, Peter P. Reese, Leroy Storsley, John S. Gill, et al.

    Young women wishing to become living kidney donors frequently ask whether nephrectomy will affect their future pregnancies. We conducted a retrospective cohort study of living kidney donors involving 85 women (131 pregnancies after cohort entry) who were matched in a 1:6 ratio with 510 healthy nondonors from the general population (788 pregnancies after cohort entry). Kidney donations occurred between 1992 and 2009 in Ontario, Canada, with follow-up through linked health care databases until March 2013. Donors and nondonors were matched with respect to age, year of cohort entry, residency (urban or rural), income, number of pregnancies before cohort entry, and the time to the first pregnancy after cohort entry. The primary outcome was a hospital diagnosis of gestational hypertension or preeclampsia. Secondary outcomes were each component of the primary outcome examined separately and other maternal and fetal outcomes. Gestational hypertension or preeclampsia was more common among living kidney donors than among nondonors (occurring in 15 of 131 pregnancies [11%] vs. 38 of 788 pregnancies [5%]; odds ratio for donors, 2.4; 95% confidence interval, 1.2 to 5.0; P=0.01). Each component of the primary outcome was also more common among donors (odds ratio, 2.5 for gestational hypertension and 2.4 for preeclampsia). There were no significant differences between donors and nondonors with respect to rates of preterm birth (8% and 7%, respectively) or low birth weight (6% and 4%, respectively). There were no reports of maternal death, stillbirth, or neonatal death among the donors. Most women had uncomplicated pregnancies after donation. Gestational hypertension or preeclampsia was more likely to be diagnosed in kidney donors than in matched nondonors with similar indicators of baseline health. (Funded by the Canadian Institutes of Health Research and others.)